Mesoblast's Ryoncil® posts $36M Q4 revenue, $115M full-year, driven by strong pediatric demand.

Mesoblast Limited reported net revenue of $36 million for the fourth quarter and $115 million for the full fiscal year ending June 30, 2026, driven by strong sales of its FDA-approved cellular therapy Ryoncil® for pediatric steroid-refractory acute graft-versus-host disease. The company highlighted continued growth momentum in major U.S. pediatric centers and a strong capital position supported by a new five-year facility. Mesoblast plans to expand Ryoncil®'s use to other inflammatory diseases and adult patients, while advancing its pipeline of cell therapies for heart failure and chronic pain. This performance underscores Mesoblast's leadership in allogeneic cellular medicines and positions it for further growth in the coming fiscal year.